Startup profile · funding coverage
Ventus Therapeutics funding, valuation and investors
Structure-based drug discovery biotech targeting 'undruggable' proteins via ReSOLVE platform.
Keep track of Ventus Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$140M · February 2022
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$140M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Waltham, Massachusetts
Investors in latest funding
Lead: SoftBank Vision Fund 2 , RA Capital Management
Other: Andreessen Horowitz
Overview
Ventus Therapeutics discovers small-molecule drugs using its ReSOLVE platform, which combines structural biology and computational chemistry to drug proteins previously considered undruggable. The Waltham, Massachusetts company focuses on immunology and inflammatory disease targets. Ventus raised a $140M Series C in February 2022 co-led by SoftBank Vision Fund 2 and RA Capital Management with participation from Andreessen Horowitz, GV, and Versant Ventures among others.
Why Ventus Therapeutics is interesting
ReSOLVE computational chemistry platform designs small molecules against difficult protein targets — $140M Series C from SoftBank and RA Capital with a16z on cap table.
Product & use cases
Ventus' ReSOLVE platform integrates protein structure determination, physics-based modeling, and medicinal chemistry to design selective small molecules. Internal pipeline programs target innate immunity and inflammatory pathways where structural insights unlock novel binding sites.
- Internal drug programs advancing novel small molecules for immunology targets
- Partnership-ready structural biology insights for difficult protein classes
- Academic and biotech collaboration on structure-enabled lead optimization
Key facts
- Series C (Feb 2022): $140M co-led by SoftBank Vision Fund 2 and RA Capital; a16z participated — Ventus press
- ReSOLVE platform for structure-based small-molecule discovery
- Waltham, MA; focused on immunology and inflammatory targets
Funding history (newest first)
Series C
2022-02 $140M- SoftBank Vision Fund 2 (lead)
- RA Capital Management (lead)
- Andreessen Horowitz (participant)
Investors in our directory
Funds linked from Ventus Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: ReSOLVE's integration of structural data with iterative chemistry differentiates from pure AI-in-silico shops — Ventus generates proprietary structural insights on targets competitors have abandoned.
Structure-based drug discovery had a mixed public-market reception (Relay, etc.) but remains credible for hard targets. Ventus' $140M Series C funded pipeline expansion pre-downturn. SoftBank and RA Capital lead signals late-stage private biotech scale. Clinical readouts — not platform claims — determine ultimate value.
-
Relay Therapeutics direct
Structure-based drug discovery; public biotech with overlapping computational chemistry thesis.
-
Schrodinger adjacent
Computational chemistry platform vendor; Ventus is asset-owning biotech using internal platform.
-
Recursion adjacent
AI-driven discovery at scale; different modality emphasis but competing for biotech investor capital.
Notable stories
- Ventus launched ReSOLVE to systematize drugging proteins without obvious druggable pockets — combining cryo-EM and computational design (Ventus press).
- The $140M Series C in February 2022 positioned Ventus to advance multiple internal programs before the biotech funding environment cooled (company announcement).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Ventus Therapeutics's financing or category context.
FAQs about Ventus Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.